Correction of dysfunctional fatty acid metabolism using peroxisome proliferator activated receptor γ agonists

Journal of the Royal Society of Medicine, Supplement

Volumn 95, Issue 42, 2002, Pages 33-38

  Oakes, Nicholas D ^a   Ljung, Bengt ^a   Camejo, Germán ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DARGLITAZONE; FATTY ACID; PALMITIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; ROSIGLITAZONE; TRIACYLGLYCEROL; TRITIUM;

ADIPOSE TISSUE; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOSCLEROSIS; ATHEROGENESIS; ATHEROSCLEROSIS; CONFERENCE PAPER; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DYSLIPIDEMIA; FATTY ACID METABOLISM; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT;

ADIPOSE TISSUE; ANIMALS; ARTERIOSCLEROSIS; FATTY ACIDS; HUMANS; PEROXISOME PROLIFERATORS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 0036344243     PISSN: 02675331     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (36)

1. The glucose-fatty acid cycle: Its role in insulin sensitivity and metabolic disturbances of diabetes mellitus
2. Regulatory interactions between lipids and carbohydrates: The glucose fatty acid cycle after 33 years
3. Contribution of muscle and liver to glucose-fatty acid cycle in humans
4. Fatty acids, lipotoxicity and insulin secretion
5. Heterogeneity of apolipoprotein B-100-containing lipoproteins: What we have learnt from kinetic studies
6. Hypertriglyceridemic hyperapob: The unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus
7. Changes in matrix proteoglycans induced by insulin and fatty acids in hepatic cells may contribute to dyslipidemia of insulin resistance
8. Impaired free fatty acid suppression during hyperinsulinemia is a characteristic finding in familial combined hyperlipidemia, but insulin resistance is observed only in hypertriglyceridemic patients
9. Systemic and regional free fatty acid metabolism in type 2 diabetes
10. Impaired free fatty acid utilization by skeletal muscle in non-insulin-dependent diabetes mellitus
11. Skeletal muscle triglyceride levels are inversely related to insulin action
12. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: A 1H NMR spectroscopy study
13. Long-chain acyl-CoA esters as indicators of lipid metabolism and insulin sensitivity in rat and human muscle
14. Nonalcoholic fatty liver disease: A feature of the metabolic syndrome
15. Non-alcoholic steatohepatitis: Another disease of affluence
16. Lipotoxic heart disease in obese rats: Implications for human obesity
17. A novel mouse model of lipotoxic cardiomyopathy
18. Chronic inhibition of fatty acid oxidation: New model of diastolic dysfunction
19. Metabolic cardiomyopathies
20. Clinical profiles of plain versus sustained-release niacin (Niaspan) and the physiologic rationale for nighttime dosing
21. Influence of nicotinic acid on serum cholesterol in man
22. Peroxisome proliferator-activated receptor-gamma: From adipogenesis to carcinogenesis
23. Peroxisome proliferator-activated receptors: From transcriptional control to clinical practice
24. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability
25. Leptin receptor missense mutation in the fatty Zucker rat
26. The use of a non-ionic detergent (Triton WR 1339) to determine rates of triglyceride entry into the circulation of the rat under different physiological conditions
27. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators
28. Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner
29. Tissue-specific actions of antidiabetic thiazolidinediones on the reduced fatty acid oxidation in skeletal muscle and liver of Zucker diabetic fatty rats
30. Peroxisome proliferator-activated receptor (PPAR) gamma and retinoid X receptor (RXR) agonists have complementary effects on glucose and lipid metabolism in human skeletal muscle
31. Lipotoxic diseases of nonadipose tissues in obesity
32. Peroxisosme proliferator-activated receptor alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis
33. Gemfibrozil for the secundary prevention of coronary heart disease in men with low levels of high density lipoprotein
34. Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk
35. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The diabetes atherosclerosis intervention study, a randomized study